DELAVIRDINE MESYLATE IN TRIPLE & QUADRUPLE COMBINATIONS IN HIV 1

甲磺酸地拉韦啶三重装

• 批准号: 6263876
• 负责人: Joseph J Eron
• 金额: $ 0.02万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263876
• 关键词: AIDS therapy; HIV infections; clinical research; combination chemotherapy; delavirdine; drug screening /evaluation; human subject; human therapy evaluation; indinavir; lamivudine; virus RNA; zidovudine

The purpose of this study is to compare the safety and tolerance of combination therapies of delavirdine, zidovudine, indinavir, and lamivudine; and to compare the antiviral activity of these combinations as measured by the change from baseline in CD4 cell count and plasma HIV-1 RNA PCR levels, the percent of patients whose plasma HIV-1 RNA PCR level drops below 5000 copies/mL, and the percent of patients whose plasma HIV-1 RNA PCR level falls below the level of detection.

本研究的目的是比较德拉韦丁、齐多夫定、茚那韦和拉米夫定联合治疗的安全性和耐受性；并通过CD4细胞计数和血浆HIV-1 RNA PCR水平的基线变化来比较这些组合的抗病毒活性，血浆HIV-1 RNA PCR水平低于5000拷贝/mL的患者百分比，血浆HIV-1 RNA PCR水平低于检测水平的患者百分比。